Skip to main content

LCD L39086: Treatment of Males with Low Testosterone

LCD L39086, Treatment of Males with Low Testosterone, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2022-05-05 and first in force 2022-02-13. The policy text runs 596 words, and its billing and coding article A58828 lists 39 ICD-10-CM codes that support medical necessity for 9 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 39 covered ICD-10-CM codes: 28 more codes than L36538 (Noridian Healthcare Solutions, LLC, 11 codes, revised 2025-10-16).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2022-05-05
Original effective
2022-02-13
Policy text
596 words
Covered ICD-10 codes (articles)
39

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39086
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A58828: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A58828 (Billing and Coding: Treatment of Males with Low Testosterone) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A58828: Billing and Coding: Treatment of Males with Low Testosterone (Billing and Coding, effective 2026-10-01)

Covered ICD-10-CM codes
39
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
9
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A58828
ICD-10-CMDescription (FY2027)
D35.2Benign neoplasm of pituitary gland
D44.3Neoplasm of uncertain behavior of pituitary gland
E23.0Hypopituitarism
E23.1Drug-induced hypopituitarism
E23.3Hypothalamic dysfunction, not elsewhere classified
E23.6Other disorders of pituitary gland
E23.7Disorder of pituitary gland, unspecified
E29.1Testicular hypofunction
E29.8Other testicular dysfunction
E30.0Delayed puberty
E89.5Postprocedural testicular hypofunction
F64.0Transsexualism
F64.1Dual role transvestism
F64.2Gender identity disorder of childhood
F64.8Other gender identity disorders
F64.9Gender identity disorder, unspecified
N44.00Torsion of testis, unspecified
N44.01Extravaginal torsion of spermatic cord
N44.02Intravaginal torsion of spermatic cord
N44.03Torsion of appendix testis
N44.04Torsion of appendix epididymis
N45.2Orchitis
N50.89Other specified disorders of the male genital organs
Q53.00Ectopic testis, unspecified

Procedure codes: 11980, 84403, 84410, 96372, J1071 (Injection, testosterone cypionate, 1 mg), J1072 (Injection, testosterone cypionate (azmiro), 1 mg), J3121 (Injection, testosterone enanthate, 1 mg), J3145 (Injection, testosterone undecanoate, 1 mg), J3490 (Unclassified drugs).

Coverage indications, limitations and medical necessity

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

Covered Indications

Treatment with testosterone is medically reasonable and necessary when prescribed for:

• Symptomatic hypogonadism (congenital or acquired) due to a disorder of the testicles, pituitary gland, or brain

• Delayed male puberty

• Gender dysphoria in a member who is able to make an informed decision to engage in hormone therapy

This A/B MAC expects that the establishment of a diagnosis of primary hypogonadism will be undertaken with at least 2 separate fasting serum testosterone levels, taken on 2 different days, drawn prior to 10 AM, and obtained from identical laboratories. A single luteinizing hormone (LH) or follicle stimulating hormone (FSH) level will also be drawn. Elevated LH/FSH confirms primary hypogonadism and the potential need for replacement hormone. If the 2 testosterone determinations are low AND the LH/FSH level(s) are also low, pituitary disease (including a serum prolactin) or chronic diseases should be assessed. ONLY secondary hypogonadism that is due to a medical disorder of the testicles, pituitary gland, or brain will be considered reasonable and necessary for treatment with testosterone. Prescribing and monitoring parameters will include:

• Prostate-specific antigen (PSA) testing must be done within the last 12 months prior to prescribing testosterone AND there will be ongoing monitoring throughout therapy.

• Hematocrit must be evaluated prior to prescribing testosterone AND there will be ongoing monitoring throughout therapy.

• Digital prostate exam must be done within the last 12 months prior to prescribing testosterone AND there will be ongoing monitoring throughout therapy.

• Where replacement is indicated, the dose of replacement therapy should be the least amount necessary to obtain a serum testosterone in the low normal range. There will be ongoing monitoring of testosterone levels throughout therapy.

• Testosterone replacement can be administered by many routes. The current preferred routes are by transdermal preparations.

• Due to United States (U.S.) Food and Drug Administration (FDA) listed warnings about possible thromboembolic disease, increase in erythrocythemia, cardiovascular risk, and stroke, the clinical records shall reflect that these issues were discussed with the patient before initiating therapy.

• Documentation of the symptoms, signs, physical examination, and required laboratory tests must be available in the chart if requested.

Limitations

The following uses of testosterone are considered NOT medically reasonable and necessary:

• Patients with hypogonadism due to aging also known as late-onset hypogonadism (LOH)

• Idiopathic hypogonadism not due to disorder of the testicles, pituitary gland, or brain

• Male menopause

• Patients with a breast cancer diagnosis

• Patients with a prostate cancer diagnosis unless previously undergone a radical prostatectomy and disease free for at least 2 years

• Patients with thrombophilia or patients who have had a myocardial infarction (MI), cardiac revascularization, or a stroke within the past 6 months

• Patients with a prostate nodule or induration, a PSA > 4 ng/mL or > 3 ng/mL in men at increased risk of prostate cancer (e.g., African American men or those who have a first-degree relative with diagnosed prostate cancer)

• Patients with a hematocrit > 48%

• Patients interested in reproduction

Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this policy, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS National Coverage Determinations (NCDs), and all Medicare payment rules.

The redetermination process may be utilized for consideration of services performed outside of the reasonable and necessary requirements in this Local Coverage Determination (LCD).

Summary of evidence (opening)

Background

Testosterone is the main androgen secreted by the testes, and the testes are the major source of circulating androgens in males. Testosterone is present in the body in 3 forms: free testosterone (FT), albumin bound testosterone, and testosterone bound to serum hormone binding globulin (SHBG). Albumin bound testosterone readily dissociates to FT. SHBG tightly binds the testosterone it carries and this form is not bioavailable. Testosterone levels are controlled by interaction of the testicular-pituitary-hypothalamic axis. Primary hypogonadism is failure of the testes to produce testosterone and is accompanied by elevated LH and/or FSH . Causes of primary hypogonadism include, but are not limited to, Klinefelter syndrome (KS), cryptorchidism, some types of chemotherapy, radiation to the testes, trauma, torsion, infectious orchitis, human immunodeficiency virus (HIV) infection, anorchia syndrome, and myotonic dystrophy. Secondary hypogonadism is disruption of the testicular-pituitary-hypothalamic pathway. These patients will typically have low or normal LH and FSH levels. Causes of secondary hypogonadism include hyperprolactinemia; severe obesity; iron overload syndromes; the use of opioids, glucocorticoids, or androgen-deprivation therapy with gonadotropin-releasing hormone agonists; androgenic–anabolic steroid (AAS) withdrawal syndrome; idiopathic hypogonadotropic hypogonadism; hypothalamic or pituitary tumors or infiltrative disease; head trauma; and pituitary surgery or radiation. In other cases, the decline in gonadal function, as may occur gradually with aging, may not be a clearly pathological process. This process is known as LOH. 1 As men age, their serum concentrations of total testosterone (TT) gradually decrease. Furthermore, SHBG increases with age, thus the normal course of aging is to further decrease the total bioavailable testosterone.

Testosterone products have been approved by the FDA for replacement therapy in men with primary or secondary hypogonadism caused by specific, well-recognized medical conditions. On the basis of this replacement use, the FDA has required only that testosterone products reliably bring low serum testosterone concentrations into the normal range, defined as the concentrations seen in healthy young men. The FDA has not mandated that clinical trials show improvements in signs or symptoms of hypogonadism in order for a testosterone product to be approved. 2

Testosterone prescriptions for men have increased substantially in recent years. One study found that in 2011, 3.7% of the men 60 years or older were taking some form of testosterone. 3 Yet, as many as 25% of the 11 million men over the age of 40 who were prescribed such treatment had not undergone testosterone testing in the 12 months prior to beginning an androgen. 4 This increase in prescribing may be due to direct to consumer marketing for “low testosterone syndrome” as well as conflicting prescribing guidelines. 5

The contractor cites 45 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2022-02-13
Current revision effective
2022-05-05
Last reviewed by the contractor
2022-03-17
MCD version
10

Other related documents: A58958 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39086 cover?

Treatment with testosterone is medically reasonable and necessary when prescribed for: The full 596-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39086 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39086?

The companion billing and coding article A58828 lists 39 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39086?

A denial under LCD L39086 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A58828's 39 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.